(NASDAQ: UPB) Upstream Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 48%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 43.33%.
Upstream Bio's earnings in 2025 is -$122,774,000.On average, 6 Wall Street analysts forecast UPB's earnings for 2025 to be -$154,128,869, with the lowest UPB earnings forecast at -$157,284,723, and the highest UPB earnings forecast at -$147,525,353. On average, 6 Wall Street analysts forecast UPB's earnings for 2026 to be -$178,689,409, with the lowest UPB earnings forecast at -$242,017,234, and the highest UPB earnings forecast at -$151,497,190.
In 2027, UPB is forecast to generate -$207,129,919 in earnings, with the lowest earnings forecast at -$373,352,625 and the highest earnings forecast at -$133,907,628.